TORONTO and HAIFA, Israel, Feb. 27, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, announced today its participation in two international conferences taking place in March 2026. Dr. Lior Shaltiel, PhD, Chief Executive Officer of NurExone, commented, “Engaging with scientific, industry, and investor audiences is a core part of our strategy, and March includes two ...

Fourth-quarter gross profit was $175.2 million , or 78% of net product revenue, compared with 75% in the prior-year period. Francisco attributed the change primarily to a shift in product mix.Total fourth-quarter revenue also included $0.5 million of grant income from the Rhode Island Life Science Hub, which the company said offset employee-related costs at its Smithfield facility.CFO Dave Francisco reported fourth-quarter net product revenue of $225.1 million , up 78% year-over-year and up 50% sequentially ...

Mesoblast (NasdaqGS:MESO) H1 2026 Earnings call February 26, 2026 05:00 PM ET Company ParticipantsJames O'Brien - Chief Financial OfficerMarcelo Santoro - Chief Commercial OfficerPaul Hughes - Head of Corporate Finance and Investor RelationsSilviu Itescu - Chief Executive Officer and Managing DirectorConference Call ParticipantsEdward Tenthoff - Managing Director and Senior Research AnalystMadeleine Williams - Analyst, Equity ResearchMichael Okunewitch - Senior Research Analyst, BiotechnologyOlivia Brayer - ...

Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) is one of the best up and coming penny stocks to buy. On February 4, Regentis Biomaterials appointed Ori Gon as Chief Financial Officer and Chief Business Officer to lead the company’s financial strategy and commercial development. Gon joined the regenerative medicine firm as its lead product, GelrinC, nears commercial launch in Europe and progresses through a pivotal Phase III FDA trial in the US. With over 15 years of experience in medtech and capital mark ...

Summary of FibroBiologics Special Meeting of Stockholders Company Overview - **Company**: FibroBiologics (NasdaqGM:FBLG) - **Industry**: Biotechnology, specifically focusing on regenerative medicine and fibroblast technology Key Points from the Meeting Corporate Governance - The meeting was presided over by Pete O'Heeron, Founder, Chairman, and CEO, with other board members and executives present [2][17] - A quorum was established with 54,971,343 votes representing approximately 56% of the total votes available [5] Proposals Voted On 1. **Reverse Stock Split**: Proposal to amend the certificate of incorporation for a reverse stock split at a ratio between 1-for-5 and 1-for-30, approved [9][15] 2. **Issuance of Shares**: Multiple proposals to approve the issuance of shares upon the exercise of outstanding common warrants, all approved: - Up to 12,110,203 shares from a securities purchase agreement dated November 18, 2025 [10][15] - Up to 4,477,614 shares from agreements dated November 24, 2025, and 313,433 shares from an engagement letter dated November 10, 2025 [11][15] - Up to 5,227,275 shares from agreements dated December 14, 2025, and 365,909 shares from an engagement letter [12][15] 3. **Adjournment of Meeting**: Approved to solicit additional votes if necessary [13][15] Corporate Update Highlights - **Mission**: To harness the immune modulation and regenerative potential of fibroblasts to treat and cure chronic diseases [18] - **Clinical Trials**: - Currently conducting a Phase 1/2 clinical trial for diabetic foot ulcers [19] - IND submitted for psoriasis at the end of December 2025, with plans for IND-ready assets for multiple sclerosis and degenerative disc disease [19] - **Financial Position**: Clean balance sheet with $4.9 million in cash as of September 30, 2025, and over 270 issued and pending patents [19][20] Technology and Innovation - **Fibroblast Technology**: - Fibroblasts are positioned as a promising alternative to stem cells for regenerative medicine due to their regenerative and immune-modulating properties [21][22] - Fibroblasts are abundant, well-characterized, and offer advantages in non-invasive sourcing, immune modulation, and cost-effectiveness [22][23] - **Pipeline**: Focus on diabetic foot ulcers, multiple sclerosis, degenerative disc disease, and psoriasis, with potential applications in longevity and cancer treatment [30][31][32] Market Opportunity - **Diabetic Foot Ulcers**: Approximately 33 million diabetes patients develop diabetic foot ulcers, representing a significant commercial opportunity [24] - **Multiple Sclerosis**: Affects 2.9 million globally, with a focus on addressing root causes rather than just symptom management [27] - **Psoriasis**: Affects 123 million worldwide, with current treatments being inadequate; fibroblast modulation offers a new approach [30] Future Outlook - The company aims to become a leader in regenerative medicine, focusing on impactful innovations rather than size [19] - Plans to advance clinical trials and potentially bring products to market rapidly, contingent on FDA approvals and trial results [36] Additional Insights - The meeting emphasized the importance of innovation, teamwork, and a commitment to curing chronic diseases rather than merely managing symptoms [19][20] - The leadership team has over 60 years of combined experience in medical innovation and capital markets, providing strategic guidance for the company's direction [20] This summary encapsulates the key discussions and proposals from the FibroBiologics special meeting, highlighting the company's strategic focus on fibroblast technology and its potential to transform the treatment of chronic diseases.

Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - February 20, 2026) - Sernova Biotherapeutics (TSX: SVA) (OTC: SEOVF) (FSE: PSH0) ("the Company"), a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes (T1D), today announced that, subject to approval from the TSX, the Company intends to amend some of its outstanding warrants.The Company issued 20,852,100 warrants pursuant to a private placement unit offering on Sep ...

Core Insights - Adia Nutrition Inc. is expanding its clinical research pipeline with plans to launch four to five new studies in 2026, focusing on regenerative therapies using Adia Vita, which is derived from umbilical cord blood [1][4]. Clinical Research Expansion - The planned studies will be conducted at the Adia Med clinic in Winter Park, Florida, and in collaboration with partner clinics across the U.S. [3] - The company is actively seeking Institutional Review Board (IRB) approvals to facilitate multi-site participation for these studies [3][4]. Focus Areas of New Studies - Priority efforts include expanding the existing Autism Spectrum Disorder (ASD) study to include children aged 13, and launching a new study on the effects of Adia Vita in patients with rheumatoid arthritis [8]. - The ongoing ASD study is actively recruiting children aged 3-12 and has received IRB approval [4]. Business Model and Revenue Generation - Adia Nutrition generates revenue through service fees, product sales, equity stakes, and billing insurance for healthcare treatments [9]. - The company is also investing in aligned businesses, such as Cement Factory LLC, to enhance its focus on health and wellness [9]. Commitment to Ethical Standards - All research conducted by Adia Med is under strict ethical oversight, informed consent, and regulatory compliance [5]. - The company emphasizes its commitment to advancing regenerative medicine through rigorous and ethical clinical research [4]. Strategic Partnerships - Adia Med is open to strategic partnerships with clinic owners and healthcare practitioners interested in licensing its name or integrating its regenerative therapies into their practices [6]. - Collaborations with leading clinics are aimed at accelerating IRB approvals and broadening patient access [4].

Core Insights - The company reported a Q4 adjusted EBITDA margin of 20.8% and adjusted diluted EPS of $0.69, with a year-over-year margin decline attributed to lower test and measurement volume and higher operating expenses [1] - The company experienced stable to improving trends across most end markets, with adjusted EBITDA and adjusted EPS at or above the high end of guidance ranges, and a robust free cash flow conversion of 117% for the full year [2] - The company anticipates 2025 to be a pivotal year, focusing on long-term strategy, innovation, and culture enhancement post-separation, with Q4 revenue of $555 million, reflecting a 1% year-over-year increase [3] Financial Performance - Q4 revenue was $555 million, exceeding guidance, with a 1% year-over-year increase and a 5% sequential growth [4][3] - The company recorded a $1.4 billion non-cash goodwill impairment related to the Elektro-Automatik acquisition due to weakened EV demand and industry forecasts [6][9] - Free cash flow for Q4 was $92 million, with a full-year conversion rate of 117%, and the company ended the quarter with $319 million in cash and 1.9x net leverage [7][8] Guidance and Outlook - For 2026, the company guided revenue of $2.1 to $2.2 billion, an adjusted EBITDA margin of 18% to 20%, and adjusted EPS of $2.22 to $2.42, noting near-term margin pressure from structural costs and increased reinvestment [5][22] - The first quarter of 2026 is expected to see revenue between $508 million and $522 million, representing 5% to 8% year-over-year growth [18] - The company expects a sequential quarterly revenue increase throughout 2026, with adjusted EBITDA margin reflecting a year-over-year decline due to structural cost changes post-spin [18] Strategic Initiatives - The company is focusing on three strategic pillars: operating discipline through the Ralliant Business System, deepening market positions, and expanding in growth vectors such as defense, energy, and electronics [13] - Organic reinvestment is prioritized, with CapEx expected to be 2%-3% of revenue in 2026, up from about 2% historically [14] - The company has authorized a quarterly cash dividend of $0.05 per share and has a $200 million share repurchase authorization remaining [15] Segment Performance - In Q4, organic revenue was flat year-over-year, with pricing actions and healthy demand in Sensors and Safety Systems offset by lower test and measurement volume [11] - The Sensors and Safety Systems segment saw a 6% year-over-year revenue increase, while the Test and Measurement segment experienced a 6% year-over-year decline [16]

Core Viewpoint - Apollo Biowellness, Inc. has terminated its Exclusive Distribution Agreement with Revive Regenerative, Inc. and is shifting its strategy to manage distribution and marketing internally [1][4]. Group 1: Termination of Agreement - The Exclusive Distribution Agreement between Evolutionary Biologics and Revive Regenerative has been terminated for cause, as disclosed to Revive [1]. - The termination allows Apollo Biowellness to resume management of its distribution and marketing efforts through its own initiatives and non-exclusive agreements [3]. Group 2: Strategic Direction - The company is moving in a new direction, with plans to announce further details shortly [4]. - Jim Morrison, the founder of Apollo Biowellness, is returning as CEO to lead the company in this new direction [4]. Group 3: Company Overview - Apollo Biowellness, Inc. and its subsidiary, Evolutionary Biologics, focus on the discovery, development, and marketing of products aimed at improving human health, particularly in the field of Regenerative Medicine [5]. - The company is developing natural stem cell mobilizing agents and a dual acting diet aid, targeting both consumer and professional markets [5].

Core Viewpoint - Adia Nutrition Inc. has achieved a significant milestone by having its Form 10 registration statement become effective, transitioning the company to full reporting status under SEC regulations, which enhances transparency and prepares for potential uplisting to NASDAQ [1][2][3] Group 1: Company Developments - The Form 10 was filed on December 5, 2025, and became effective automatically 60 days later without further SEC review, marking a transition to full reporting status [2] - CEO Larry Powalisz emphasized that this achievement reflects the company's commitment to governance and investor confidence, while also accelerating preparations for uplisting to NASDAQ [3] - The company is expanding its regenerative medicine platform and clinic network, focusing on advanced treatments in stem cell therapy [3] Group 2: Financial and Operational Highlights - Adia Nutrition generates revenue through service fees, product sales, equity stakes, and insurance billing for healthcare treatments [7] - The company is experiencing significant revenue growth and operational expansion in 2025, positioning itself for continued momentum in personalized healthcare [8] - Adia Nutrition is also investing in aligned businesses, such as Cement Factory LLC, which focuses on health and wellness [7] Group 3: Strategic Partnerships and Initiatives - The company is encouraging clinic owners and healthcare practitioners to license the Adia Med name or integrate its regenerative therapies into their practices [5] - Adia Nutrition is forming strategic partnerships to expand access to advanced stem cell solutions [5] - The company is involved in ongoing clinical studies, including an IRB-approved study on autism spectrum disorder using regenerative stem cell therapy [8]